Pharmaceutical

Dragonfly and Gilead enter partnership for cancer therapy

Dragonfly Therapeutics has entered a clinical collaboration with Gilead Sciences to assess DF1001 plus Trodelvy for cancer indications.

Feb 16, 2024 - 18:00
Dragonfly and Gilead enter partnership for cancer therapy
Dragonfly Therapeutics has entered a clinical collaboration with Gilead Sciences to assess DF1001 plus Trodelvy for cancer indications.
Read the original article

Tags:

Previous Article

Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan

Next Article

FDA grants orphan drug status to Ionis’ olezarsen for FCS treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

U.S. government spent more on health care in 2022 than six countries with universal health care combined

U.S. government spent more on health care in 2022 than ...

Dec 19, 2023

STAT+: Pharmalittle: Health care mergers facing tougher antitrust scrutiny; tornado hits Pfizer plant and more shortages may result

STAT+: Pharmalittle: Health care mergers facing tougher...

Jul 20, 2023

After affirmative action ruling, medical education leaders see silver lining in court endorsement of ‘holistic review’

After affirmative action ruling, medical education lead...

Jun 30, 2023